NCT05467397 2026-01-21
Feasibility of [11C]Acetate-PET in LAM and TSC
Brigham and Women's Hospital
Phase 1/2 Active not recruiting
Clinical Trials
13 trialsNCT02849457 2024-08-19
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
University of Alabama at Birmingham
Phase 2 Completed
NCT04595513 2024-05-16
STOP2
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT00126672 2022-04-25
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02451696 2021-09-01
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NYU Langone Health
Phase 2 Completed
NCT01929642 2021-03-29
RAPT
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT01526356 2020-10-26
Treatment
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02201212 2020-09-16
Everolimus for Cancer With TSC1 or TSC2 Mutation
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02061397 2020-08-25
SOS
University of Pennsylvania
Phase 1/2 Completed
NCT01289912 2018-01-25
TSC
Boston Children's Hospital
Phase 2 Completed
NCT01266291 2017-07-12
STARS
University of Pennsylvania
Phase 4 Terminated
NCT01070316 2017-03-13
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT00411619 2014-10-20
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed